Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): A randomized, double-blind, placebo-control
暂无分享,去创建一个
M. Pencina | B. Zinman | J. Rosenstock | C. Wanner | V. Perkovic | R. Toto | J. Alexander | Darren K Mcguire | M. Cooper | N. Marx | U. Broedl | H. Woerle | J. George | David Baanstra | E. Pfarr | M. Mattheus | E. M. Von